Nicholas Richardson

8PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesMolecular targetsHaematological tumoursMedical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 12, 2026
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.

Richard Scott Swain, Andrew Klink, Parisa Asgarisabet

|Jul 15, 2025
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma.

Kristen Britton, Upendra Mahat, Nicholas C Richardson

|Oct 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.

Maryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu

|Dec 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.

Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco

|Apr 03, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.

Nadia Howlader, Elad Sharon, Manami Bhattacharya

|Mar 09, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.

Andrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon

Pageof 2

Frequent Collaborators

4 joint publications

Marc R Theoret

4 joint publications

Nicole J Gormley

3 joint publications

Richard Pazdur

2 joint publications

Maryam Sarraf Yazdy